All Posts

For years, the honest answer to "is anyone working on a treatment for NDI?" was: not really, not yet. That answer has changed. A Phase 1 clinical trial is now enrolling for NDI-5001, an investigational treatment for nephrogenic diabetes insipidus (NDI, also known as AVP-R). It is sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. The first research site is in Jacksonville, Florida, and more may open as the trial progresses. This is a milestone for our co

A possible treatment for X-linked congenital NDI is moving closer to human study. NDI-5001 is now part of a registered Phase 1b trial, giving families a meaningful sign of progress while research continues.

For families living with X-linked NDI, the daily reality is relentless. Producing up to 20 liters of urine a day, managing constant thirst, planning every outing around water access — and doing all of it with no real treatment in sight. Just management. Just coping. That may be beginning to change.